Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen expects key drugs like Repatha, Evenity, Tezspire and oncology and rare disease drugs, as well as biosimilars to drive ...

Investing.com -- Fitch Ratings has revised its outlook for biopharmaceutical company Amgen Inc (NASDAQ: AMGN ). to positive ...

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Amgen (AMGN) concluded the recent trading session at $318.65, signifying a +0.47% move from its prior day's close.

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

MariTide’s opportunity in diabetes should not be ignored. In addition to reducing weight by 17%, it reduced HbA1c up to 2.2% ...

Amgen’s $400 million eczema drug candidate has recorded two more phase 3 victories. The data drops provide more evidence that ...

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

The general mood among these heavyweight investors is divided, with 70% leaning bullish and 20% bearish. Among these notable ...

Amgen (AMGN) gains traction with a 26% YTD rise, strong earnings, and a robust dividend. Analysts signal growth potential ...